Psychedelic substances such as LSD, psilocybin and MDMA have increasingly become the focus of science and clinical practice in recent years. The substances are used as part of so-called psychedelic-assisted therapies (PAT), in which psychotherapeutic treatment is combined with the temporary administration of these substances. After research and clinical use largely came to a standstill in the 1970s, modern, controlled studies are now available that provide promising but not yet conclusive data on efficacy and safety.
Autoren
- PD Dr. med. Felix Müller
- Dr. phil. Helena D. Aicher
- Prof. Dr. med. Undine E. Lang
Publikation
- InFo NEUROLOGIE & PSYCHIATRIE
Related Topics
You May Also Like
- Psychedelic-assisted therapy
Current status of PAT
- Neuropathic Pain
Evidence-Based Neuromodulation Based on Clinical Trials and Real-World Data
- Fibromyalgia Syndrome
Development, Diagnosis, Epidemiology, and Treatment of a Disease Entity
- Juvenile Idiopathic Arthritis
Early Detection and Targeted Treatment in an Interdisciplinary Setting
- Disorders of the Gut-Brain Interaction
Rome V Criteria: What Has Changed, and What Has Remained the Same?
- Tourette Syndrome
What can be done to treat this tic disorder?
- Chronic Hepatitis B: Is a Cure in Sight?
Phase III Trial of Temporary Treatment with Bepirovirsen Was Successful
- Congenital Vascular Malformations